[Effect of calcium pangamate on the cholesterol index of atherogenicity in cerebral arteriosclerosis patients].
Calcium pangamate (CP) in patients with the cerebrasthenic syndrome of atherosclerotic genesis facilitates a decrease in the cholesterol index of atherogenicity due to increased levels of serum high-density lipoproteins (HDLP). One of the factors contributing to an increase in HDLP levels in the patients' blood serum under the impact of CP is the stimulation of the phospholipid incorporation into HDLP.
D000368:Aged; D002125:Calcium Gluconate; D002784:Cholesterol / Q000097:blood*; D002908:Chronic Disease; D003704:Dementia / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D008074:Lipoproteins / Q000097:blood; D008875:Middle Aged; D034442:N-substituted Glycines; D010743:Phospholipids / Q000097:blood; D011379:Prognosis; D011437:Propylamines; D014803:Vitamin B Complex / Q000627:therapeutic use*
D008074:Lipoproteins; D034442:N-substituted Glycines; D010743:Phospholipids; D011437:Propylamines; D014803:Vitamin B Complex; D002784:Cholesterol; C105565:pangamic acid; D002125:Calcium Gluconate
Vliianie pangamata kal'tsiia na kholesterinovyĭ indeks aterogennosti u bol'nykh tserebral'nym aterosklerozom.